Physician profile
John P Anders
NPI 1811932643
$6,494.37
in general payments reported to CMS, 2019-2025
32 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $685 · 2021: $1,035 · 2022: $1,045 · 2023: $802 · 2024: $937 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,744 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,744.41 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,657.65 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,032.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $446.96 | 2021-2025 | Sotyktu |
| Janssen Biotech, INC. | $424.06 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $319.56 | 2019-2025 | |
| Amgen INC. | $315.92 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $277.52 | 2020-2025 | Nemluvio |
| Incyte Corporation | $213.81 | 2021-2023 | Opzelura |
| Genzyme Corporation | $212.36 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $202.64 | 2019-2024 | Dupixent |
| Ucb, INC. | $198.82 | 2020-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $170.58 | 2019-2025 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $160.87 | 2019-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $135.00 | 2021-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.28 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $90.74 | 2020-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $83.31 | 2020-2021 | |
| Epi Health, LLC | $58.97 | 2019 | |
| Celgene Corporation | $52.63 | 2019 | |
| Botanix Sb INC | $41.04 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $38.74 | 2019 | |
| Dermavant Sciences, INC. | $37.46 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $30.50 | 2023 | |
| Prugen, INC. Pharmaceuticals | $30.31 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $24.76 | 2019 | |
| Journey Medical Corporation | $20.00 | 2023 | |
| Sandoz INC. | $18.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.63 | 2023 | Cyltezo |
| Krystal Biotech INC | $16.30 | 2025 | Vyjuvek |
| Encore Dermatology INC. | $14.97 | 2020 | |
| Dermira, INC. | $14.94 | 2019 | |
| Organon LLC | $2.84 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.